Cost effective assay choice for rare disease study designs

High throughput assays tend to be expensive per subject. Often studies are limited not so much by the number of subjects available as by assay costs, making assay choice a critical issue. We have developed a framework for assay choice that maximises the number of true disease causing mechanisms ‘see...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Desmond D, Porsch, Robert M, Cherny, Stacey S, Capra, Valeria, Merello, Elisa, De Marco, Patrizia, Sham, Pak C, Garcia-Barceló, Maria-Mercè
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334400/
https://www.ncbi.nlm.nih.gov/pubmed/25648394
http://dx.doi.org/10.1186/s13023-015-0226-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334400/
https://www.ncbi.nlm.nih.gov/pubmed/25648394
http://dx.doi.org/10.1186/s13023-015-0226-9

Ejemplares similares